Recently, a number of CXO listed companies have successively released their semi-annual business results. The increase in on-hand orders and the acceleration of the new molecule business have become common characteristics of the industry. In an interview with reporters, a pharmaceutical industry expert said that the current round of CXO industry recovery is showing more positive characteristics. As the pace of innovative drugs going overseas accelerates, the industry boom is expected to continue in the second half of the year.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.